

BIOCRYST PHARMACEUTICALS INC

Form 4

June 22, 2015

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
STAAB THOMAS R II

2. Issuer Name and Ticker or Trading  
Symbol  
BIOCRYST PHARMACEUTICALS  
INC [BCRX]

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)  
4505 EMPEROR BLVD., SUITE  
200

3. Date of Earliest Transaction  
(Month/Day/Year)  
06/18/2015

\_\_\_\_ Director \_\_\_\_ 10% Owner  
\_\_\_\_ Officer (give title below) \_\_\_\_ Other (specify below)  
Senior Vice President and CFO

(Street)  
DURHAM, NC 27703

4. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
\_\_\_\_ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting  
Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount (A) or (D)	Price	
Common Stock <sup>(1)</sup>	06/18/2015		S		3,500	D \$ 14	149,644 D
Common Stock <sup>(1)</sup>	06/18/2015		M		3,100	A \$ 3.78	152,744 D
Common Stock <sup>(1)</sup>	06/18/2015		M		3,100	A \$ 3.78	155,844 D
Common Stock <sup>(1)</sup>	06/18/2015		S		3,100	D \$ 14.25	152,744 D
Common Stock <sup>(1)</sup>	06/18/2015		S		3,100	D \$ 13.5	149,644 D

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

Common Stock <sup>(1)</sup>	06/19/2015	S	3,500	D	\$ 15	146,144	D
Common Stock <sup>(1)</sup>	06/19/2015	M	3,175	A	\$ 3.78	149,319	D
Common Stock <sup>(1)</sup>	06/19/2015	S	3,175	D	\$ 15	146,144	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (Right to Buy) <sup>(1)</sup>	\$ 3.78	06/18/2015		M	3,100	07/01/2012 07/01/2021	Common Stock	3,100
Stock Option (Right to Buy) <sup>(1)</sup>	\$ 3.78	06/18/2015		M	3,100	07/01/2012 07/01/2021	Common Stock	3,100
Stock Option (Right to Buy) <sup>(1)</sup>	\$ 3.78	06/19/2015		M	3,175	07/01/2012 07/01/2021	Common Stock	3,175

## Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
	Senior Vice President and CFO

STAAB THOMAS R II  
4505 EMPEROR BLVD.  
SUITE 200  
DURHAM, NC 27703

## Signatures

/s/ Alane P. Barnes, by power of  
attorney

06/22/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.